Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and norethisterone acetate

Gynecological Endocrinology

Volumn 21, Issue 2, 2005, Pages 65-73

  Gambacciani, M ^a   Spielmann, D ^b   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Searle European Clinical R and D   (France)

Author keywords

Climacteric symptoms; Continuous combined hormone replacement therapy; Estradiol; Hot flush; Menopause; Norethisterone acetate; Quality of life; Trimegestone

Indexed keywords

ESTRADIOL; NORETHISTERONE ACETATE; TRIMEGESTONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NIGHT SWEAT; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AFFECT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROMEGESTONE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SWEATING;

EID: 25144478264     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500128971     Document Type: Article

References (23)

1. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med, 1979;300:9-13.
2. Cust MP, Gangar KF, Hillard TC, Whitehead MI. A risk-benefit assessment of estrogen therapy in postmenopausal women. Drug Saf 1990;5:345-358.
3. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982;37:79-82.
4. Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992;166:1986-1992.
5. Utian WH, Burry KA, Archer DF, Gallagher JC, Boyett RL, Guy MP, Tachon GJ, Chadha-Boreham HK, Bouvet AA. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol 1999;181:71-79.
6. Stadberg E, Mattsson L-A, Uvebrant M. 17β-Estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996;23:31-39.
7. Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane PJ, Schwenker CE, Transdermal Estradiol Patch Study Group. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. Int J Fertil 1995;40:126-134.
8. Notelovitz M, Lenihan JP Jr, McDermott M, Kerber IJ, Nanavati N, Arce J-C. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731.
9. Skouby SO. The rationale for a wider range of progestogens. Climacteric 2000;3:14-20.
10. Sherwin BB. Progestogens used in menopause. Side effects, mood and quality of life. J Reprod Med 1999;44:227-232.
11. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316-326.
12. Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin:trimegestone. Steroids 2003;68:915-920.
13. Meuwissen JH, De Bie-Beijers L, Vihtamaki T, Tuimala R, Siseles N, Magaril C, The HS, Houben PW, Murga M, Spielmann D, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2001;15:349-358.
14. Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N. A comparison of the effects of continuous combined regimens of 1 mg 17β-estradiol and trimegestone with regimens containing 1 or 2 mg 17β-estradiol and noresthisterone acetate upon the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol 2005;(in press).
15. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953;13:688-703.
16. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54.
17. Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. London: European Agency for the Evaluation of Medicinal Products; 2000.
18. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180-1185.
19. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
20. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087.
21. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676.
22. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999;6:273-276.
23. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani AR. Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003;44:157-163.